Product Information

SKYRIZI 150 MG/ML SYRINGE is a brand product labeled by AbbVie Inc., priced at $22924.3662 per ML under NDC 00074105001. Its NADAC has been published 226 times since Jul 20, 2022.

SKYRIZI 150 MG/ML SYRINGE

risankizumab-rzaa
$22924.3662per ML

Strength

150 mg/mL

Manufacturer

AbbVie Inc.

NDC

00074105001

Classification

Brand

Dosage Form

INJECTION

Route

SUBCUTANEOUS

Effective Date

10/21/2026

Active Ingredients

RISANKIZUMAB

Approval Type

Biologic (BLA)

FDA Application

BLA761105

On Market Since

4/26/2021

Pharmacological Classes

Interleukin-23 Antagonist
Interleukin-23 Antagonists

Price Statistics

The NADAC for SKYRIZI 150 MG/ML SYRINGE has been published 226 times since Jul 20, 2022, and over the history we have for it it has risen 28.5%. The table below summarizes its recorded NADAC range and movement.

Current price$22924.3662 per ML
All-time high$22942.3716 (Jul 15, 2026)
All-time low$17835.5520 (Jul 20, 2022)
52-week high$22942.3716
52-week low$21542.1329
Median price$20514.4519
Average price$20615.2224
Largest weekly change+8.0% (Jan 11, 2023)
Weeks tracked226
Tracking sinceJul 20, 2022

Price History

1W

0.0%

1M

+0.2%

3M

+0.7%

6M

-0.1%

1Y

+6.5%

3Y

+19.0%

5Y

N/A

All

+28.5%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 1%

1 alternative • Same active ingredient

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of SKYRIZI 150 MG/ML SYRINGE?

The current National Average Drug Acquisition Cost (NADAC) for SKYRIZI 150 MG/ML SYRINGE, manufactured by AbbVie Inc., is $22924.3662 per ML (NDC 00074105001), effective Nov 11, 2026.

How has the price of SKYRIZI 150 MG/ML SYRINGE changed over time?

Over the history we have for it, the NADAC for SKYRIZI 150 MG/ML SYRINGE has risen 28.5%. It has been tracked across 226 weekly CMS publications since Jul 20, 2022.

What are the highest and lowest recorded NADAC prices for SKYRIZI 150 MG/ML SYRINGE?

Since Jul 20, 2022, the NADAC for SKYRIZI 150 MG/ML SYRINGE has ranged from a low of $17835.5520 (Jul 20, 2022) to a high of $22942.3716 (Jul 15, 2026), with a median of $20514.4519 per ML.

Are there cheaper alternatives to SKYRIZI 150 MG/ML SYRINGE?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SKYRIZI 150 MG/ML PEN, is $22795.0931 per ML — about 1% below SKYRIZI 150 MG/ML SYRINGE.

Who manufactures SKYRIZI 150 MG/ML SYRINGE?

SKYRIZI 150 MG/ML SYRINGE (NDC 00074105001) is labeled by AbbVie Inc., and CMS classifies it as a brand product.